Southern medical journal
-
Southern medical journal · May 2021
Meta AnalysisSafety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
We evaluated the safety of baricitinib 4 mg at 24 weeks for the treatment of moderate to severe rheumatoid arthritis (RA). ⋯ Patients with RA taking 4 mg baricitinib daily did have an increased risk of infections; however, the incidence of serious adverse events, adverse events leading to study discontinuation, or serious infections were not significantly different in patients treated with baricitinib 4 mg compared with placebo.